Radiotherapy in Oligometastatic PCa and Treating the Primary in De Novo Oligometastatic PCa 

Daniel A. Hamstra, MD, PhD, FASTRO, FASCO, Professor and Chair of Radiation Oncology at Baylor College of Medicine in Houston, Texas, discusses the use of radiotherapy in oligometastatic prostate cancer treatment and how to approach treating the primary in de novo oligometastatic disease. In this 30-minute presentation, Dr. Hamstra covers:
- The history and definition of oligometastatic disease.
- The history of radiation therapy in localized and metastatic prostate cancer.
- Results from the STAMPEDE, PEACE-1, and STOMP and ORIOLE trials.
- The Pros and Cons of including radiation therapy in systemic therapy.
- Progression to Survival and Overall Survival rates in radiation therapy patients.
- The need for more data comparing low-volume and high-volume oligometastatic patients.